UBS Group
BJDX icon

UBS Group’s Bluejay Diagnostics BJDX Stock Holding History

UBS Group’s Portfolio BJDX Stock Details BJDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-124
Closed -$228 – 10458
2026
Q1 		$228 Buy
+124
New +$306 ﹤0.01% 10017
2025
Q3 		– Sell
-111
Closed -$764 – 10345
2025
Q2 		$764 Sell
111
-92
-45% -$753 ﹤0.01% 9745
2025
Q1 		$3.03K Sell
203
-283
-58% -$4.34K ﹤0.01% 9256
2024
Q4 		$9.47K Buy
486
+179
+58% +$3.34K ﹤0.01% 8356
2024
Q3 		$7.8K Buy
+307
New +$22K ﹤0.01% 7873
2023
Q3 		– Hold
0
– -$1.36K – 9469
2023
Q2 		– Hold
0
– – – 7938
2023
Q1 		– Hold
0
– -$3.82K – 9619
2022
Q4 		– Hold
0
– – – 9445
2022
Q3 		– Hold
0
– – – 8403
2022
Q2 		– Hold
0
– – – 10321
2022
Q1 		– Hold
0
– – – 8951
2021
Q4 		– Hold
0
– – – 8433

Other funds holding BJDX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
LGM
L1 Global Manager Melbourne $142M AUM
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

UBS Group's BJDX Position: Q2 2026 in Review

UBS Group sold out of Bluejay Diagnostics (BJDX) in Q2 2026, closing a stake of 124 shares — an estimated $228 sold.

UBS Group first reported a position in BJDX in Q3 2024 and held it in 5 quarters. The position peaked at $9.47K in Q4 2024. 8 funds tracked by Wall St. Rank hold BJDX as of Q2 2026.

  • UBS Group reported no remaining Bluejay Diagnostics position as of Q2 2026 after selling out during the quarter.
  • UBS Group sold 124 Bluejay Diagnostics shares in Q2 2026, an estimated $228.
  • UBS Group first reported a position in Bluejay Diagnostics in Q3 2024 and held it in 5 quarters.
  • UBS Group's Bluejay Diagnostics position peaked at $9.47K in Q4 2024.
  • 8 funds tracked by Wall St. Rank held Bluejay Diagnostics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.